By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Joining the Anti-PD-L1 Cancer Drug Market, Syndax Inks Deal With Genentech (RHHBY), Closes on $80 Million Series C Round 8/26/2015 6:34:54 AM
Constellation Pharma Mulls IPO After Genentech (RHHBY) Declines to Buy 8/25/2015 6:25:12 AM
AstraZeneca PLC (AZN) Taps Genentech (RHHBY)’s Sean Bohen as New Chief Medial Officer 8/24/2015 6:00:24 AM
Genentech (RHHBY) Throws Cancers in a Basket to Detect Tumors at Their Genetic Roots 8/20/2015 6:45:10 AM
Pivotal Phase II Study Showed Genentech (RHHBY)’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Lung Cancer 8/17/2015 6:15:14 AM
Genentech (RHHBY)'s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial 8/17/2015 6:12:58 AM
Genentech (RHHBY) Ramps Up Partnerships for Next-Gen Cancer Drugs 8/13/2015 6:34:32 AM
Genentech (RHHBY), AbbVie (ABBV) Confirm Venetoclax Met Primary Endpoint in Phase II Study 8/12/2015 7:53:43 AM
In A Pivotal Study, Genentech (RHHBY)’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Bladder Cancer 7/13/2015 6:19:34 AM
Genentech (RHHBY)’s Breakthrough Atezolizumab Joins Club of Successful Anti-PD-L1 Drugs, Shrinks Tumors in Bladder Cancer 7/13/2015 6:18:41 AM